Prevention is better than cure for killer cardiovascular disease

July 6, 2012

European experts in cardiovascular medicine will today gather at a two day symposium to address the national agenda on cardiovascular disease prevention, held at Imperial College London and sponsored by leading independent academic and professional publisher SAGE.

One session at the conference, chaired by Professors Joep Perk and David Wood will focus on the new 2012 Joint European Societies' Guidelines on prevention in clinical practice, which will appear in August issue (volume 19, issue 4) of the European Society of Cardiology's European Journal of Preventive Cardiology, published by SAGE.

Our chances of succumbing to cardiovascular disease (CVD) are strongly connected to our lifestyles. Smoking, an unhealthy diet, , and stress can all take their toll. According to The (WHO), over three-quarters of all CVD mortality could be prevented with adequate .

CVD prevention is a society-wide effort, and needs a co-ordinated set of actions at both public and individual level. Health experts use and evidence based medicine to uncover the most effective paths to prevention.

In the new joint European Guidelines, healthcare providers will find answers to key questions including:

  • What is CVD prevention?
  • Why is it needed?
  • Who should benefit from it?
  • How can CVD prevention be applied?
  • When is the right moment to act?
  • Where should prevention programmes be provided and implemented?
According to the experts behind the review, atherosclerotic CVD (furring of the arteries) remains the leading cause of premature death worldwide. CVD affects both men and women; of all deaths that occur before age 75 in Europe, 42% are due to CVD in women and 38% in men.

Prevention works. Over 50% of the reductions seen in coronary relate to changes in risk factors, and 40% to improved treatments. This is a lifelong endeavour – we should begin efforts to prevent CVD from birth – if not before.

In terms of prevention, the experts say it's not just those most at risk that should be targeted. Education programmes aimed at the entire population are still needed. Even though there are some gaps in our understanding, there is ample evidence to justify intensive public health and individual preventive efforts.

We still need to better understand why both populations and individuals change their behaviour – exactly how changes in behaviour translate into changes in disease patterns is not always understood. More research, including research that goes right back to foetal development, is needed to better prevent CVD. We still don't know whether preventative measures can help us to completely avoid CVD, or whether these efforts merely delay its onset. We also need more data on CVD morbidity and mortality throughout the world.

This version of the joint guidelines updates the previous one issued in 2007. There is a greater focus on new scientific knowledge, and grading systems are deployed, which allow more evidence-based recommendations to be adapted to clinical practice's requirements.

The Fifth Joint Task Force (JTF) of the and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, made up of representatives of nine societies plus invited experts, developed the new guidelines. The European Association for Cardiovascular Prevention & Rehabilitation (EACPR) also contributed. Experts from the nine organizations performed a comprehensive review and a critical evaluation of diagnostic and therapeutic procedures, including assessment of the risk benefit ratio. The level of evidence and the strength of recommendation of particular treatment options were weighed and graded according to ESC recommendations.

"The authors of the guidelines hope that this document will advocate a real partnership among politicians, physicians, allied health personnel, scientific associations, heart foundations, voluntary organizations, and consumers' associations. Using the complete spectrum of evidence in medicine from experimental trials to observations in populations, the aim is to foster both health promotion at the population level and primary and cardiovascular at the clinical level" the JTF concluded.

Explore further: NAFLD independently linked to cardiovascular disease

More information: "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)"published today, 05 July 2012 in European Journal of Preventive Cardiology.

www.escardio.org/guidelines

Related Stories

NAFLD independently linked to cardiovascular disease

June 7, 2012
(HealthDay) -- Nonalcoholic fatty liver disease (NAFLD) is independently associated with an increased risk of cardiovascular disease (CVD), but it is not associated with a statistically significantly increased risk of cardiovascular ...

Benchmarking study prompts rethink on next cardiovascular disease prevention guidelines

February 22, 2012
Sophia Antipolis, Wednesday 22 February 2012: The next Joint European CVD Prevention Guidelines, scheduled for publication later this year at EuroPRevent 2012, will be shorter, tighter and supported by fewer references. The ...

First joint ESC/EAS guidelines for the management of dyslipidaemias

June 28, 2011
Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of ...

New guidelines deliver concise messages for implementing cardiovascular prevention

May 3, 2012
The latest cardiovascular disease (CVD) prevention guidelines have been overhauled to produce a user friendly document with concise messages that awards greater weight than ever before to evidence from clinical trials and ...

Increasing cardiovascular disease in China: Urgent need for prevention

October 12, 2011
At over 40%, the mortality rate due to cardiovascular disease (CVD) in China is amongst the highest in the world¹ and has been rightly described as an epidemic.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.